Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Structure of Lipids03:38

Structure of Lipids

Lipids include a diverse group of compounds that are largely nonpolar in nature. This is because they are hydrocarbons that include mostly nonpolar carbon-carbon or carbon-hydrogen bonds. Non-polar molecules are hydrophobic (“water fearing”), or insoluble in water. Lipids perform many different functions in a cell. Cells store energy for long-term use in the form of fats. Lipids also provide insulation from the environment for plants and animals. For example, they help keep aquatic birds and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Omega-3 index improves upon the pooled cohort equation in predicting risk for CVD.

Journal of clinical lipidology·2025
Same author

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.

Blood·2022
Same author

Prospective Evaluation of Clinico-Pathological Predictors of Postoperative Atrial Fibrillation: An Ancillary Study From the OPERA Trial.

Circulation. Arrhythmia and electrophysiology·2020
Same author

Cancer in chronic heart failure patients in the GISSI-HF trial.

European journal of clinical investigation·2020
Same author

Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins - Confirmation from PCSK9 Inhibitor Studies.

The American journal of medicine·2019
Same author

IGENDA protocol: gender differences in awareness, knowledge and perception of cardiovascular risk: an Italian multicenter study.

Journal of cardiovascular medicine (Hagerstown, Md.)·2019

Related Experiment Video

Updated: May 8, 2026

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

n-3 PUFAs and heart failure.

Roberto Marchioli1, Giacomo Levantesi2

  • 1Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy.

International Journal of Cardiology
|September 10, 2013
PubMed
Summary
This summary is machine-generated.

Omega-3 polyunsaturated fatty acids (n-3 PUFAs) show promise in reducing mortality and hospitalizations for heart failure (HF) patients. Further research is needed to confirm these benefits in large-scale clinical trials for HF treatment.

Keywords:
Heart failurePrognosisReviewTreatment

More Related Videos

Quantifying Food Intake in Caenorhabditis elegans by Measuring Bacterial Clearance
07:05

Quantifying Food Intake in Caenorhabditis elegans by Measuring Bacterial Clearance

Published on: February 23, 2024

Related Experiment Videos

Last Updated: May 8, 2026

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

Quantifying Food Intake in Caenorhabditis elegans by Measuring Bacterial Clearance
07:05

Quantifying Food Intake in Caenorhabditis elegans by Measuring Bacterial Clearance

Published on: February 23, 2024

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure (HF) remains a significant cause of mortality despite advances in diagnosis and treatment.
  • Omega-3 polyunsaturated fatty acids (n-3 PUFAs) have demonstrated cardiovascular benefits in other patient populations.

Purpose of the Study:

  • To assess the effects of n-3 PUFAs on mortality and cardiovascular hospitalizations in patients with heart failure.
  • To evaluate n-3 PUFAs as a potential life-prolonging therapy for HF.

Main Methods:

  • Analysis of results from the GISSI-HF trial, a large-scale clinical trial on n-3 PUFAs in HF patients.

Main Results:

  • Treatment with n-3 PUFAs in 100 HF patients was associated with nearly 2 lives saved and 2 fewer cardiovascular hospitalizations.
  • These findings suggest that the cardiovascular benefits of n-3 PUFAs may extend to HF patients.

Conclusions:

  • n-3 PUFAs may be considered a valuable addition to evidence-based therapies for HF.
  • Further large-scale clinical trials are necessary to address remaining questions regarding n-3 PUFAs in HF treatment.